[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
aponia_analytics @AponiaAnalytics on x 5030 followers
Created: 2025-07-20 21:27:43 UTC
🦉 REWIND showed dulaglutide reduced MACE in lower-risk T2DM patients; benefits driven by nonfatal stroke. But XX% discontinued by study end. Tolerability remains a limiting factor in long-term outcomes.
#GLP1 #stroke $NVO $LLY $ZLDPF $VANI $HIMS $AZN
XXX engagements
Related Topics manat $hims $vani $zldpf $lly longterm $nvo stocks healthcare